CNXC vs CX: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: CNXC is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CNXC and CX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CNXC and CX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Concentrix Corporation runs customer support, sales, trust-and-safety and back-office operations for large companies, staffing contact centers in dozens of countries and increasingly layering software and AI agents on top through its iX Suite. It was spun out of SYNNEX in December 2020 and roughly doubled in size by buying Webhelp in 2023. Revenue is close to $10 billion a year, spread across technology, retail and travel, banking and insurance, healthcare and other verticals, with long-tenured top clients (the company cites 16+ years average tenure for its top 25).

Full CNXC guide

Cemex (NYSE: CX) is a global building-materials company that makes and sells cement, ready-mix concrete, and aggregates (crushed stone, sand, and gravel), along with related urbanization and infrastructure products. It operates across five reportable segments (Mexico, the United States, Europe, the Middle East and Africa, and South, Central America and the Caribbean), with the US and Mexico together accounting for roughly 60% of 2025 revenue. The US-listed security is an ADR representing the underlying Mexican shares; the company is one of the largest cement producers in the world alongside Holcim, Heidelberg Materials, and CRH.

Full CX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CNXC drivers: Selling AI into the installed base; Cash flow and deleveraging.
• CX drivers: US aggregates and infrastructure tilt; Margin self-help and efficiency programs.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The core risk is that generative AI lets clients handle more customer contacts themselves or through AI-native vendors, shrinking the volume of paid human support faster than Concentrix can replace it with software revenue. For CX, cemex is a deeply cyclical business whose demand swings with construction and infrastructure spending, so a downturn or higher-for-longer interest rates could pressure volumes and pricing.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CNXC if you believe its drivers more; CX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CNXC and CX guides.

CNXC. On non-GAAP numbers CNXC trades at roughly 2.4x fiscal 2026 earnings and near 2.5x adjusted free cash flow, a valuation that prices in a sustained decline rather than stability. GAAP results show a net loss because of the ~$1.05B Q3 goodwill impairment, which is non-cash but tied directly to the lower stock price. Including debt, enterprise value is roughly $5.7B, or about 4x annualized non-GAAP operating income. For comparison, fiscal 2025 revenue was $9.83B (+2.2%), operating cash flow was $807M and adjusted free cash flow was $626M, so the 2026 cash guidance is roughly flat on a year earlier despite lower revenue. Management has said it expects fiscal 2027 adjusted free cash flow to be higher again, helped by lower restructuring costs, cash interest and capital spending. In June 2026 it had cut full-year non-GAAP EPS guidance to $10.83 to $11.18 from $11.48 to $12.07 and flagged about $175M of restructuring charges.

CX. Cemex trades around $12 per ADR with a trailing P/E in the high 30s but a forward P/E near 18, reflecting expectations of rising earnings as efficiency programs and US aggregates flow through. Full-year 2025 revenue was roughly flat versus 2024, but adjusted profitability improved sharply on cost savings and pricing. Figures are approximate and based on 2025 filings and Q1 2026 results.

Headline figures (approximate, October 2026): CNXC shows revenue (ttm) ~$9.9B, fiscal 2026 revenue guidance ~$9.83B to $9.88B, non-gaap eps (fy2026 guidance) ~$10.97 to $11.09, market cap ~$1.6B (share price ~$26); CX shows revenue (2025 fy) ~$16.1B, revenue (q1 2026, yoy) ~$4.0B (+11%), ebitda (q1 2026) ~$794M (+34%), adjusted net income (2025) ~$1.5B.

CNXC and CX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CNXC and CX exposure against your real portfolio. It is not an investment adviser.